Press Releases
CV6 Therapeutics Appoints Dr. Chris Takimoto to Board of Directors
CV6 Therapeutics today announced the appointment of veteran oncology drug developer Dr. Chris Takimoto to its Board of Directors as the company advances its lead program, CV6-168, through Phase 1a clinical development.
CV6 Therapeutics Joins QUBIS “Spin Out to Stand Out” Event at Queen’s University Belfast
CV6 Therapeutics was proud to participate in “Spin Out to Stand Out,” a recent alumni and innovation event hosted by Queen's University Belfast and QUBIS on Wednesday, 29 April 2026, highlighting the strength of Northern Ireland’s growing entrepreneurial ecosystem.